Annual CFF
$353.32 M
+$97.68 M+38.21%
December 31, 2023
Summary
- As of February 12, 2025, AKRO annual cash flow from financing activities is $353.32 million, with the most recent change of +$97.68 million (+38.21%) on December 31, 2023.
- During the last 3 years, AKRO annual CFF has risen by +$150.21 million (+73.96%).
- AKRO annual CFF is now at all-time high.
Performance
AKRO Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$3.07 M
+$3.22 M+2144.67%
September 30, 2024
Summary
- As of February 12, 2025, AKRO quarterly cash flow from financing activities is $3.07 million, with the most recent change of +$3.22 million (+2144.67%) on September 30, 2024.
- Over the past year, AKRO quarterly CFF has increased by +$2.26 million (+280.52%).
- AKRO quarterly CFF is now -99.16% below its all-time high of $366.94 million, reached on March 31, 2024.
Performance
AKRO Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$370.36 M
+$2.26 M+0.61%
September 30, 2024
Summary
- As of February 12, 2025, AKRO TTM cash flow from financing activities is $370.36 million, with the most recent change of +$2.26 million (+0.61%) on September 30, 2024.
- Over the past year, AKRO TTM CFF has increased by +$14.82 million (+4.17%).
- AKRO TTM CFF is now -47.47% below its all-time high of $705.10 million, reached on March 31, 2024.
Performance
AKRO TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
AKRO Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +38.2% | +280.5% | +4.2% |
| 3 y3 years | +74.0% | +4344.9% | +10000.0% |
| 5 y5 years | +315.6% | +290.9% | +285.8% |
AKRO Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | >+9999.0% | -99.2% | +2144.7% | -47.5% | >+9999.0% |
| 5 y | 5-year | at high | >+9999.0% | -99.2% | +2144.7% | -47.5% | >+9999.0% |
| alltime | all time | at high | >+9999.0% | -99.2% | +290.9% | -47.5% | >+9999.0% |
Akero Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $3.07 M(-2144.7%) | $370.36 M(+0.6%) |
| Jun 2024 | - | -$150.00 K(-100.0%) | $368.10 M(-47.8%) |
| Mar 2024 | - | $366.94 M(>+9900.0%) | $705.10 M(+99.6%) |
| Dec 2023 | $353.32 M(+38.2%) | $502.00 K(-37.7%) | $353.32 M(-0.6%) |
| Sep 2023 | - | $806.00 K(-99.8%) | $355.54 M(-37.9%) |
| Jun 2023 | - | $336.86 M(+2123.0%) | $572.63 M(+111.6%) |
| Mar 2023 | - | $15.15 M(+456.5%) | $270.65 M(+5.9%) |
| Dec 2022 | $255.63 M(>+9900.0%) | $2.72 M(-98.8%) | $255.63 M(+1.0%) |
| Sep 2022 | - | $217.90 M(+524.8%) | $253.15 M(+616.7%) |
| Jun 2022 | - | $34.88 M(>+9900.0%) | $35.32 M(+4874.8%) |
| Mar 2022 | - | $132.00 K(-45.7%) | $710.00 K(+17.9%) |
| Dec 2021 | $602.00 K | $243.00 K(+252.2%) | $602.00 K(+44.0%) |
| Sep 2021 | - | $69.00 K(-74.1%) | $418.00 K(-99.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | $266.00 K(+1008.3%) | $203.13 M(+0.1%) |
| Mar 2021 | - | $24.00 K(-59.3%) | $202.97 M(-0.1%) |
| Dec 2020 | $203.11 M(+111.6%) | $59.00 K(-100.0%) | $203.11 M(-0.0%) |
| Sep 2020 | - | $202.78 M(>+9900.0%) | $203.16 M(<-9900.0%) |
| Jun 2020 | - | $100.00 K(-39.0%) | -$1.23 M(-101.3%) |
| Mar 2020 | - | $164.00 K(+42.6%) | $96.87 M(+0.9%) |
| Dec 2019 | $95.99 M(+12.9%) | $115.00 K(-107.2%) | $95.99 M(-42.2%) |
| Sep 2019 | - | -$1.61 M(-101.6%) | $166.10 M(-1.0%) |
| Jun 2019 | - | $98.20 M(<-9900.0%) | $167.70 M(+99.0%) |
| Mar 2019 | - | -$720.00 K(-101.0%) | $84.29 M(-0.8%) |
| Dec 2018 | $85.01 M | $70.22 M(>+9900.0%) | $85.01 M(+475.0%) |
| Sep 2018 | - | $0.00(-100.0%) | $14.78 M(0.0%) |
| Jun 2018 | - | $14.78 M(>+9900.0%) | $14.78 M(>+9900.0%) |
| Mar 2018 | - | $0.00 | $0.00 |
FAQ
- What is Akero Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Akero Therapeutics?
- What is Akero Therapeutics annual CFF year-on-year change?
- What is Akero Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Akero Therapeutics?
- What is Akero Therapeutics quarterly CFF year-on-year change?
- What is Akero Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Akero Therapeutics?
- What is Akero Therapeutics TTM CFF year-on-year change?
What is Akero Therapeutics annual cash flow from financing activities?
The current annual CFF of AKRO is $353.32 M
What is the all time high annual CFF for Akero Therapeutics?
Akero Therapeutics all-time high annual cash flow from financing activities is $353.32 M
What is Akero Therapeutics annual CFF year-on-year change?
Over the past year, AKRO annual cash flow from financing activities has changed by +$97.68 M (+38.21%)
What is Akero Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of AKRO is $3.07 M
What is the all time high quarterly CFF for Akero Therapeutics?
Akero Therapeutics all-time high quarterly cash flow from financing activities is $366.94 M
What is Akero Therapeutics quarterly CFF year-on-year change?
Over the past year, AKRO quarterly cash flow from financing activities has changed by +$2.26 M (+280.52%)
What is Akero Therapeutics TTM cash flow from financing activities?
The current TTM CFF of AKRO is $370.36 M
What is the all time high TTM CFF for Akero Therapeutics?
Akero Therapeutics all-time high TTM cash flow from financing activities is $705.10 M
What is Akero Therapeutics TTM CFF year-on-year change?
Over the past year, AKRO TTM cash flow from financing activities has changed by +$14.82 M (+4.17%)